Persistent Corneal Epithelial Defects Treatment Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight
DelveInsight’s “Persistent Corneal Epithelial Defects Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects pipeline landscape. It covers the Persistent Corneal Epithelial Defects pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Persistent Corneal Epithelial Defects pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Persistent Corneal Epithelial Defects Pipeline. Dive into DelveInsight’s comprehensive report today! @ https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight
Key Takeaways from the Persistent Corneal Epithelial Defects Pipeline Report
- DelveInsight’s Persistent Corneal Epithelial Defects pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Persistent Corneal Epithelial Defects treatment.
- The leading Persistent Corneal Epithelial Defects Companies such as Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
- Promising Persistent Corneal Epithelial Defects Pipeline Therapies such as ST266, KIO-201, Lufepirsen high dose and others.
Stay ahead with the most recent pipeline outlook for Persistent Corneal Epithelial Defects. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Persistent Corneal Epithelial Defects Treatment Drugs
The Persistent Corneal Epithelial Defects Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Persistent Corneal Epithelial Defects Pipeline Report also highlights the unmet needs with respect to Persistent Corneal Epithelial Defects.
Persistent Corneal Epithelial Defects Overview
The cornea is the transparent, outermost layer of the eye that uniformly refracts the majority of light that enters the eye onto the lens and is essential for ideal vision. The multi-layered corneal epithelium acts as a protective barrier to infectious agents via tight junctions between neighboring cells, and it maintains its smooth optical surface by constantly regenerating cells in the basal cell layer. Persistent Corneal Epithelial Defects (PCEDs) (PEDs or PCEDs) result from the failure of rapid re-epithelialization and closure within 10-14 days after a corneal injury, even with standard supportive treatment. Disruptions in the protective epithelial and stromal layers of the cornea can render the eye susceptible to infection, stromal ulceration, perforation, scarring, and significant vision loss.
Persistent Corneal Epithelial Defects Emerging Drugs Profile
- KPI-012: Kala Pharmaceuticals
Kala’s development pipeline includes KPI-012, in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. Kala is also evaluating KPI-012 for potential expansion to additional indications for rare front of the eye diseases, such as partial limbal stem cell deficiency and moderate-to-severe Sjögren’s. KPI-012 is currently under investigation for PCED in Phase II trial which is expected to be completed in February 2024.
- Nexagon: Eyevance/Amber Ophthalmics
NEXAGON, is a first in class unmodified antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43). Cx43 is overexpressed after acute injury or in chronic disease states leading to pathological prematurely open hemichannels, allowing ATP to enter the extracellular space. Extracellular ATP triggers and perpetuates the immune system’s inflammasome pathway releasing multiple proinflammatory cytokines resulting in microvascular breakdown, vessel leak and limbal tissue ischemia. NEXAGON inhibits Cx43 overexpression and the inflammatory cascade, re-establishing limbal microvasculature and promoting regeneration of the corneal epithelium. Amber Ophthalmics, of San Diego, which is currently developing Nexagon reported that it saw positive topline results in a Phase II trial of Nexagon (lufepirsen ophthalmic gel) for persistent corneal epithelial defect (PCED) secondary to chemical and/or thermal injury. Nexagon has been granted orphan drug status by the US FDA. Amber said it plans to begin a Phase II/III trial in subjects with PCED of various etiologies in Q1-2023.
Explore groundbreaking therapies and clinical trials in the Persistent Corneal Epithelial Defects Pipeline. Access DelveInsight’s detailed report now! @ New Persistent Corneal Epithelial Defects Drugs
The Persistent Corneal Epithelial Defects Pipeline Report Provides Insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Persistent Corneal Epithelial Defects with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Persistent Corneal Epithelial Defects Treatment.
- Persistent Corneal Epithelial Defects Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Persistent Corneal Epithelial Defects Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Persistent Corneal Epithelial Defects market
Persistent Corneal Epithelial Defects Companies
Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
Persistent Corneal Epithelial Defects pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Persistent Corneal Epithelial Defects Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Unveil the future of Persistent Corneal Epithelial Defects Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Persistent Corneal Epithelial Defects Market Drivers and Barriers
Scope of the Persistent Corneal Epithelial Defects Pipeline Report
- Coverage- Global
- Persistent Corneal Epithelial Defects Companies- Eyevance/Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma and others.
- Persistent Corneal Epithelial Defects Pipeline Therapies- ST266, KIO-201, Lufepirsen high dose and others.
- Persistent Corneal Epithelial Defects Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Persistent Corneal Epithelial Defects Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Persistent Corneal Epithelial Defects Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Persistent Corneal Epithelial Defects Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Persistent corneal epithelial defects (PCEDs): Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Persistent corneal epithelial defects (PCEDs)– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Mid Stage Products (Phase II)
- KPI-012: Kala Pharmaceuticals
- Early Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- OC-01: Oyster Point Pharma
- Inactive Products
- Persistent corneal epithelial defects (PCEDs) Key Companies
- Persistent corneal epithelial defects (PCEDs) Key Products
- Persistent corneal epithelial defects (PCEDs)- Unmet Needs
- Persistent corneal epithelial defects (PCEDs)- Market Drivers and Barriers
- Persistent corneal epithelial defects (PCEDs)- Future Perspectives and Conclusion
- Persistent corneal epithelial defects (PCEDs) Analyst Views
- Persistent corneal epithelial defects (PCEDs) Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight
